


**MEDICINAL PRODUCTS 2020** 

**ONCOCYTE** 

Oncocyte Corp
Rank 31 of 52







**MEDICINAL PRODUCTS 2020** 

**Oncocyte Corp** 

Rank 31 of 52



The relative strengths and weaknesses of Oncocyte Corp are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Oncocyte Corp compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 38% points. The greatest weakness of Oncocyte Corp is the variable Net Income, reducing the Economic Capital Ratio by 51% points.

The company's Economic Capital Ratio, given in the ranking table, is 15%, being 20% points above the market average of -4.3%.

Input Variable	Value in 1000 USD
Assets, Current	22,956
Assets, Non-Current	10,964
General and Administrative Expense	15,445
Goodwill	0
Liabilities, Current	4,440
Liabilities, Non-Current	0
Other Assets	5,939
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	4,581
Other Net Income	-187
Other Revenues	0
Property, Plant and Equipment, Net	0
Research and Development	6,794

Output Variable	Value in 1000 USD
Liabilities	9,021
Assets	39,859
Expenses	22,239
Revenues	0
Stockholders Equity	30,838
Net Income	-22,426
Comprehensive Net Income	-22,426
Economic Capital Ratio	15%

